Association between a polymorphism in the promoter region of dopamine D2 receptor gene and schizophrenia in Japanese subjects: Replication and evaluation for antipsychotic-related features

International Journal of Neuropsychopharmacology

Volumn 2, Issue 3, 1999, Pages 181-186

  Inada, Toshiya ^a   Arinami, Tadao ^b   Yagi, Gohei ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dopamine D2 receptor gene; Extrapyramidal symptoms; Promoter region; Schizophrenia; Tardive dyskinesia

Indexed keywords

EID: 0012736360     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001492     Document Type: Article

References (22)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (revised 3rd ed.). Washington, DC: American Psychiatric Association.
2. Arinami T, Gao M, Hamaguchi H, Toru M (1997). A functional polymorphism in the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics 6, 577-582.
3. Cravchik A, Sibley DR, Gejman PV (1996). Functional analysis of the human D2 dopamine receptor missense variants. Journal of Biological Chemistry 271, 26013-26017.
4. 11C]raclopride. Psychopharmacology (Berlin) 107, 23-29.
5. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum P, Delisi LE, Virkkunen M, Linnoila M, Goldman D, Gershon ES (1994). No structural mutation in the dopamine D2 receptor gene in alcoholism and schizophrenia. Journal of the American Medical Association 271, 204-208.
6. Gelernter J, Kranzler H, Cubells JF, Ichinose H, Nagatsu (1998). DRD2 allele frequencies and linkage disequilibria, including the -141C Ins/Del promoter polymorphism, in European-American, African-American, and Japanese subjects. Genomics 51, 21-26.
7. Inada T (1996). Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo: Seiwa Publishers Inc.
8. Inada T, Dobashi I, Sugita T, Inagaki A, Kitao Y, Matsuda G, Kato S, Takano T, Yagi G, Asai M (1997). Search for a susceptibility locus to tardive dyskinesia. Human Psychopharmacology 12, 35-39.
9. Inada T, Sugita T, Dobashi I, Inagaki A, Kitao Y, Matsuda G, Kato S, Takano T, Yagi G, Asai M (1995). Dopamine D3 receptor gene polymorphism and the psychiatric symptoms seen in first-break schizophrenic patients. Psychiatric Genetics 5, 113-116.
10. Inada T, Sugita T, Dobashi I, Inagaki A, Kitao Y, Matsuda G, Kato S, Takano T, Yagi G, Asai M (1996). Dopamine transporter gene polymorphism and the psychiatric symptoms seen in schizophrenic patients at their first episode. American Journal of Medical Genetics 67, 406-408.
11. Inagaki A, Inada T, Fujii Y, Yagi G (1998). Dose equivalence of psychotropic drugs. Part IV. Dose equivalence of orally administered neuroleptics (4). [In Japanese.] Rinsyo Seishin Yakuri [Japanese Journal of Clinical Psychopharmacology] 1, 443-448.
12. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M (1993). A structural polymorphism of human dopamine D2 receptor, D2 (Ser311 → Cys). Biochemical and Biophysical Research Communications 196, 1369-1375.
13. Jönsson EG, Nöthen MM, Neidt H, Forslund K, Pylander G, Mattila-Evenden MM, Åsberg M, Propping P, Sedvall GC (1998). Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. American Journal of Medical Genetics 81, 497 (abstract no. 47).
14. Kaiser R, Brockmöller J, Schmider J, Roots I (1998). Heritable polymorphisms in the dopamine and serotonin receptors in schizophrenic patients and healthy controls. American Journal of Medical Genetics 81, 518-519.
15. Kalsi G, Mankoo BS, Curtis D, Brynjolfsson J, Read T, Sharma T, Murphy P, Petursson H, Gurling HM (1995). Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. Psychological Medicine 25, 531-537.
16. Li T, Arranz M, Aitchison KJ, Bryant C, Liu X, Kerwin RW, Murray R, Sham P, Collier DA (1998). Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophrenia Research 32, 87-92.
17. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106, 433-438.
18. 2 receptor gene promoter and schizophrenia. Psychiatric Research 81, 117-123.
19. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39, 486-487.
20. Shaw SH, Kelly M, Smith AB, Shields G, Hopkins PJ, Loftus J, Laval SH, Vita A, De Hert M, Cardon LR, Crow TJ, Sherrington R, DeLisi LE (1998). A genome-wide search for schizophrenia susceptibility genes. American Journal of Medical Genetics 81, 364-376.
21. Stober G, Jatzke S, Heils A, Jungkunz G, Knapp M, Mossner R, Riederer P, Lesch KP (1998). Insertion/deletion variant (-141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. Journal of Neural Transmission 105, 101-109.
22. Su Y, Burke J, O'Neill FA, Murphy B, Nie L, Kipps B, Bray J, Shinkwin R, Ni Nuallain M, MacLean CJ, Walsh D, Diehl SR, Kendler KS (1993). Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. Archives of General Psychiatry 50, 205-211.